Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D

Andrea Morales Caceres; Kshitij  Kumar Singh; Timo Minssen; Steven J.  Hoffman; Susan Rogers Van Katwyk

doi:10.1017/jme.2022.79

Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D

Andrea Morales Caceres^*, Kshitij Kumar Singh, Timo Minssen, Steven J. Hoffman, Susan Rogers Van Katwyk

^*Corresponding author af dette arbejde

Centeret for Avancerede Studier i Biovidenskablig Innovationsret

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

30 Downloads (Pure)

Abstract

The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.

Originalsprog	Engelsk
Tidsskrift	Journal of Law, Medicine & Ethics
Vol/bind	50
Udgave nummer	S2 (Winter 2022)
Sider (fra-til)	47-54
Antal sider	8
ISSN	1073-1105
DOI	https://doi.org/10.1017/jme.2022.79
Status	Udgivet - 2022

Emneord

Det Juridiske Fakultet

Adgang til dokumentet

10.1017/jme.2022.79Licens: CC BY

Citationsformater

Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D . / Morales Caceres, Andrea; Kumar Singh, Kshitij ; Minssen, Timo; Hoffman, Steven J. ; Van Katwyk, Susan Rogers.

I: Journal of Law, Medicine & Ethics, Bind 50, Nr. S2 (Winter 2022), 2022, s. 47-54.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{4716ae9dc1f747c7aecf9fd358aa6992,

title = "Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D ",

abstract = "The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization{\textquoteright}s (WHO{\textquoteright}s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.",

keywords = "Faculty of Law, AMR, pandemic treaty, law, ethics",

author = "{Morales Caceres}, Andrea and {Kumar Singh}, Kshitij and Timo Minssen and Hoffman, {Steven J.} and {Van Katwyk}, {Susan Rogers}",

year = "2022",

doi = "10.1017/jme.2022.79",

language = "English",

volume = "50",

pages = "47--54",

journal = "Journal of Law, Medicine & Ethics",

issn = "1073-1105",

publisher = "Cambridge University Press",

number = "S2 (Winter 2022)",

}

TY - JOUR

T1 - Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D

AU - Morales Caceres, Andrea

AU - Kumar Singh, Kshitij

AU - Minssen, Timo

AU - Hoffman, Steven J.

AU - Van Katwyk, Susan Rogers

PY - 2022

Y1 - 2022

N2 - The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.

AB - The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.

KW - Faculty of Law

KW - AMR

KW - pandemic treaty

KW - law

KW - ethics

U2 - 10.1017/jme.2022.79

DO - 10.1017/jme.2022.79

M3 - Journal article

C2 - 36889345

VL - 50

SP - 47

EP - 54

JO - Journal of Law, Medicine & Ethics

JF - Journal of Law, Medicine & Ethics

SN - 1073-1105

IS - S2 (Winter 2022)

ER -